Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02367859
Title Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Stanford University
Indications

ameloblastoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST